|
CO-ADMINISTRATION HAS RESULTED IN BLEEDING AND/OR INCREASED PROTHROMBIN TIME IN FEW PATIENTS
|
CONCOMITANT USE SHOULD BE AVOIDED
|
|
CO-ADMINISTRATION MAY BE ASSOCIATED WITH INCREASED RISK OF BLEEDING
|
MAY ANTAGONISE THE EFFECTS OF AMINOCAPROIC ACID
|
MAY ANTAGONISE THE EFFECTS OF AMINOCAPROIC ACID
|
MAY ANTAGONISE THE EFFECTS OF AMINOCAPROIC ACID
|
MAY ANTAGONISE THE EFFECTS OF AMINOCAPROIC ACID
|
MAY ANTAGONISE THE EFFECTS OF AMINOCAPROIC ACID
|
MAY ANTAGONISE THE EFFECTS OF AMINOCAPROIC ACID
|
MAY ANTAGONISE THE EFFECTS OF AMINOCAPROIC ACID
|
MAY ANTAGONISE THE EFFECTS OF AMINOCAPROIC ACID
|
MAY ANTAGONISE THE EFFECTS OF AMINOCAPROIC ACID
|
MAY ANTAGONISE THE EFFECTS OF AMINOCAPROIC ACID
|
MAY ANTAGONISE THE EFFECTS OF AMINOCAPROIC ACID
|